CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma
Status:
Not yet recruiting
Trial end date:
2026-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to measure the benefit of adding abemaciclib to chemotherapy for
Ewing's sarcoma that has come back or did not respond to treatment. This trial is part of the
CAMPFIRE master protocol, which is a platform to speed development of new treatments for
children and young adults with cancer. Your participation in this trial could last 11 months
or longer, depending on how you and your tumor respond.